Top

Annals of Surgical Oncology

Published in:

01-10-2007

Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Authors: D. Baratti, MD, S. Kusamura, MD, D. Nonaka, MD, G. D. Oliva, MD, B. Laterza, MD, M. Deraco, MD

Published in: Annals of Surgical Oncology | Issue 10/2007

Abstract

Background

Multicystic peritoneal mesothelioma (MPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM) are exceedingly uncommon lesions with uncertain malignant potential and no uniform treatment strategy. The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings.

Methods

Four women with MPM and eight with WDPPM underwent 13 procedures of cytoreduction and close-abdomen HIPEC with cis-platin and doxorubicin. Seven patients had recurrent disease after previous debulking (one operation in five patients, two in one, four in one). Potential clinicopathological prognostic factors were assessed.

Results

Optimal cytoreduction (residual tumor nodules ≤2.5 mm) was performed in 12 of 13 procedures. Median follow-up was 27 months (range 6–94). One grade 4 postoperative complication (NCI/CTCAE v.3.0) and no operative mortalities occurred. One patient underwent the procedure twice due to locoregional MPM recurrence. Transition of typical WDPPM to malignant biphasic mesothelioma was documented in one patient who died of disease progression following incomplete cytoreduction and HIPEC. Following multimodality treatment, 5-year overall and progression-free survival were 90.0% (standard error = 9.0) and 79.7% (11.9), respectively. Progression-free survival following previous debulking surgery (median 24 months; range 2–87) was statistically worse (P = .0156). Incomplete cytoreduction and poor performance status correlated to both reduced overall and progression-free survival after cytoreduction and HIPEC.

Conclusions

MPM and WDPPM are borderline tumors capable of transformation into potentially lethal processes. Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.

Safioleas MC, Constantinos K, Michael S, Konstantinos G, Constantinos S, Alkiviadis K. Benign multicystic peritoneal mesothelioma: a case report and review of the literature. World J Gastroenterol 2006; 12:5739–42PubMed

Weiss SW, Tavassoli FA. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 1988; 12:737–46PubMedCrossRef

Soreide JA, Soreide K, Korner H, Soiland H, Greve OJ, Gudlaugsson E. Benign peritoneal cystic mesothelioma. World J Surg 2006; 30:560–6PubMedCrossRef

Tangjitgamol S, Erlichman J, Northrup H, Malpica A, Wang X, Lee E, Kavanagh JJ. Benign multicystic peritoneal mesothelioma: cases reports in the family with diverticulosis and literature review. Int J Gynecol Cancer 2005; 15:1101–7PubMedCrossRef

Hoekstra AV, Riben MW, Frumovitz M, Liu J, Ramirez PT. Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature. Gynecol Oncol 2005; 98:161–7PubMedCrossRef

Daya D, McCaughey EWT. Well-differentiated papillary mesothelioma of the peritoneum. Cancer 1990; 65:292–6PubMedCrossRef

Mennemeyer R, Smith M. Multicystic peritoneal mesothelioma: a case report with electron microscopy of a case mimicking intra-abdominal cystic hygroma (lymphangioma). Cancer 1979; 44:629–98CrossRef

Hanrahan JB. A combined papillary mesothelioma and adenomatoid tumor of the omentum: report of a case. Cancer 1963; 11:1497–1500CrossRef

Galateau-Salle F, Vignaud JM, Burke L, et al. Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases. Am J Surg Pathol 2004; 28:534–40PubMedCrossRef

10.

Tolhurst SR, Lotan T, Rapp DE, Lyon MB, Orvieto MA, Gerber GS, Sokoloff MH. Well-differentiated papillary mesothelioma occurring in the tunica vaginalis of the testis with controlateral atypical mesothelial hyperplasia. Urol Oncol 2006; 24:36–9PubMed

11.

Gonzalez-Moreno S, Yan H, Alcorn KW, Sugarbaker PH. Malignant transformation of benign cystic mesothelioma of the peritoneum. J Surg Oncol 2002; 79:243–51PubMedCrossRef

12.

Van Ruth S, Bronkhorst MWGA, van Coevorden F, Zoetmulder FAN. Peritoneal cystic mesothelioma: a case report and review of the literature. Eur J Surg Oncol 2002; 28:192–5PubMedCrossRef

13.

Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560–7PubMedCrossRef

14.

Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007; 14:41–9PubMedCrossRef

15.

Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Gilly FN, Glehen O. Malignant peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal chemohyperthermia: Results of a prospective study. Ann Surg Oncol 2006; 13:405–12PubMedCrossRef

16.

Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13:229–37PubMedCrossRef

17.

Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:686–91PubMedCrossRef

18.

Sethna K, Mohamed F, Marchettini P, Elias D. Sugarbaker PH. Peritoneal cystic mesothelioma: a case series. Tumori 2003; 89:31–5PubMed

19.

Hejmadi R, Ganesan R, Kamal NG. Malignant transformation of a well-differentiated peritoneal papillary mesothelioma. Acta Cytol 2003; 47:517–8PubMed

20.

Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 2005; 104:2181–8PubMedCrossRef

21.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–55PubMedCrossRef

22.

Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002; 94:492–9PubMedCrossRef

23.

Esquivel JE, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther 1998; 1:321–5

24.

Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49–58

25.

Sugarbaker PH. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727–31PubMedCrossRef

26.

http://ctep.cancer.gov/reporting/ctc_v30.html Cited April 1, 2003

27.

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–16PubMedCrossRef

28.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53:457–81

29.

Stewart JH, Perry S, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005; 12:765–77PubMedCrossRef

30.

Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: analysis of morbidity and mortality in 209 cases treated with closed abdomen technique. Cancer 2006; 106:1144–53PubMedCrossRef

31.

Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6:582–90PubMedCrossRef

32.

De Stephano DB, Wesley JR, Heidelberg KP, Hutchinson RJ, Blane CE, Coran AG. Primitive cystic hepatic neoplasm of infancy with mesothelial differentiation: report of a case. Pediatr Pathol 1985; 4:291–302

33.

Burrig KF, Pfitzer P, Hort W. Well-differentiated papillary mesothelioma of the peritoneum: a borderline mesothelioma. Report of two cases and review of the literature. Wirchows Archiv Pathol Anat 1990; 417:443–7CrossRef

Title: Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
Authors: D. Baratti, MD
S. Kusamura, MD
D. Nonaka, MD
G. D. Oliva, MD
B. Laterza, MD
M. Deraco, MD
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 10/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9475-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2007

Prescribing Patterns of Surgical Oncologists: Are We Surgeons, Oncologists, or Both?

Current Status of Tumor M2 Pyruvate Kinase (Tumor M2-PK) as a Biomarker of Gastrointestinal Malignancy

Outcomes for Women With Ductal Carcinoma-in-Situ and a Positive Sentinel Node: A Multi-Institutional Audit

Pulmonary Metastasectomy for Melanoma: Beyond the Standard of Care

Fusion of Magnetic Resonance and Scintimammography Images for Breast Cancer Evaluation: A Pilot Study

Clinicopathologic Features and Long-Term Outcomes of 293 Phyllodes Tumors of the Breast